
Britain's most hated and loved exercises - and the common household items people use to keep fit at home
Many resort to multitasking in an effort to hit activity targets, finding extra opportunities to move when cooking, cleaning and even brushing their teeth.
Over one in three people (36 per cent) say they dislike push-ups, followed by burpees (29 per cent), planks (24 per cent) and chin-ups (24 per cent).
The fearsome five is completed by crunches (22 per cent), according to the poll of 2,075 adults for Age UK's 'Act Now, Age Better' campaign.
Meanwhile, the most loved are squats (20 per cent) and lunges (14 per cent).
Age UK is encouraging people to make small, proactive changes that could help improve their physical health and the quality of their later years.
One in five people (20 per cent) stay active at home by running up and down the stairs, while 10 per cent use chairs or a sofa for tricep dips or elevated push-ups.
A time-efficient 15 per cent do exercises such as squats or lunges while waiting for the kettle to boil and 10 per cent balance on one leg while brushing their teeth.
Furthermore, 9 per cent dance while hoovering and 2 per cent squat while in the shower. Others claim they hula hoop while reading.
The findings demonstrate it is not necessary to travel to the gym to exercise, with many making use of common household items to help keep them in shape.
The most commonly used are cans or jars (11 per cent), water bottles (10 per cent), pillows or cushions (9 per cent) and towels (7 per cent).
Some 3 per cent fill their shopping bags with objects to turn them into weights. Others use oil drums, firewood logs and milk bottles filled with pebbles.
Finally, 2 per cent have their pets join them in an at-home workout, with one saying they have dance sessions with all four of their dogs, another who holds their pet on their chest as a weight while doing sit-ups and a third whose cat loves to climb on their back during yoga.
TV presenter and Strictly Come Dancing star Angela Rippon said: 'Our bodies are machines that are full of thousands of moving parts.
'And like any machine, if we don't keep those parts oiled and moving, they will seize up and let us down.
'Dancing is one of the best exercises you can do for the health and wellbeing of your mind as well as your body.
'So just let yourself go and move to the music on the radio.
'I often get up and dance to the music of the commercials that come up in my favourite TV programme.'
Dr Hussain Al-Zubaidi, a GP and personal trainer, said: 'It's easy to feel put off by the word 'exercise'.
'When it's used, we often picture someone at full blast, hot and sweaty, maybe running or lifting what seems like too much weight in an impressive gym setup.
'But 'exercise" is anything that gets us moving and it all counts. 'That's why with patients and clients I use the word 'movement'.
'Most importantly, it must be something we enjoy and feel benefit from.
'There are things we can do in our everyday lives to mimic the classic 'exercises" and still reap the benefits.
'For example, the dreaded push-up can be done against a wall or sofa rest during movement breaks after time sat down.
'Eventually, as your upper body gets stronger, you may be able to do them from the floor.
'Start adding in some jumping jacks in between push-ups and you are also then tackling similar elements to a burpee.
'To tackle elements of the plank, you can hold your push up variation for as long as you can whilst tensing your core.
'Bear crawls around the house are a fantastic way to get in some cardiovascular and strength training at the same time.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
2 minutes ago
- The Independent
Thousands of cancer patients could be undergoing unnecessary overtreatment
Up to 5,000 men in the UK could be undergoing unnecessary overtreatment for prostate cancer annually due to 'outdated' guidelines. Prostate Cancer UK warns that current National Institute of Health and Care Excellence (NICE) guidelines, last updated in 2021, do not account for advances in testing and diagnosis, leading to overtreatment. Overtreatment of slow-growing prostate cancers can result in severe side effects such as erectile dysfunction and incontinence, which could often be avoided with active monitoring. Experts describe a "wild west" or "postcode lottery" in care, with overtreatment rates varying significantly across England and many hospitals developing their own inconsistent guidelines.


Daily Mail
3 minutes ago
- Daily Mail
Mother reveals 'unimaginable' loss after son, 30, died from 'smoking vape laced with opioid 20 times more powerful than fentanyl'
A mother has revealed her heart-wrenching loss after her son allegedly died from smoking a vape laced with an opioid. Freddy Ireland-Rose, 30, died last September following an accidental overdose of nitazenes, a drug thought to be around 20 times more powerful than fentanyl. He had been using a cannabis vape in a bid to withdraw from opiates and had been buying the liquid refills on the internet, an inquest in front of the Inner North London assistant coroner Sarah Bourke previously heard. After being found unresponsive at home with the device in his hand, paramedics succeeded in rescuscitating him but he did not regain consciousness and died in hospital a few days later. Now Ireland-Rose's mother has spoken out about her 'unimaginable' loss following the death of her son, as well as the potential reasons for his overdose, in an interview with the BBC. She said: 'Once you are mother, you can't un-mother yourself, even when the person is not there. He was such a vivid personality. And it's just a vast, bottomless hole really.' The heartbroken mother also revealed Ireland-Rose had been using the same vape for two or three weeks and had been receiving Jiffy bags from Amsterdam among other places. 'I don't think for one minute, and neither do any of his friends, that he took this intentionally. So, we can only assume it was in another illicit drug that he was taking, another opioid, or that it was the vape. 'And my question at the inquest was, is it possible that this contaminated the vapes and they came back with the answer, yes it was possible.' She suggested that the nitazenes had either entered her son's system by these means or through pills, and that people's lack of awareness of the opioids was alarming. In a Prevention of Future Deaths Report, Ms Bourke previously warned about cannabis vapes being contaminated by nitazenes, normally used as a synthetic pain reliever. She added that the risk of overdose was 'significant' because the amount ingested through inhalation could 'vary enormously'. The danger was greater given the lack of access to the antidote naloxone. Ms Bourke pointed out that nitazenes have entered into the UK heroin supply, but there was no evidence to suggest Ireland-Rose had taken street heroin before his overdose. Nitazenes were first created in the 1950s as opioid painkillers but were never approved for medical use. For 70 years, their existence was forgotten. Then, after Britain and America's withdrawal from Afghanistan - and the Taliban's subsequent narcotics ban - they re-emerged as a way to strengthen low-purity heroin in case opium supplies dwindled. Experts are united in their fear of the rising risk of nitazenes. Yet, while heroin users are still vulnerable, young people buying traditionally legal drugs such as Valium and Xanax as coping mechanisms are also at risk. In fact, MailOnline analysis of data from the UK's only drug testing facility Wedinos has revealed that two-thirds of samples that contained nitazenes were supposed to be legal medications that could be purchased legally. Two-thirds of that total were bought by people intending to buy Valium (diazepam). So far, the number of nitazene-related deaths only stands at 458 in the last two years, up to April 13. However, there was a 166 per cent increase from 2023 (125 deaths) to 2024 (333 deaths) - more than double in a single year, and even that total is expected to rise once toxicology and forensic testing improves and is finalised. Steve Rolles, a senior policy analyst at the Transform Drug Policy Foundation, told MailOnline: 'The number of deaths is rising at an alarming rate. It's the tip of the iceberg. 'What has happened in the US should be a warning to policymakers in the UK. We could be heading to a US-style overdose crisis. We are talking thousands or tens of thousands dying. 'All the indications are that is what is happening. I'm very wary of scaremongering about drugs but I'm deeply worried about the potential carnage opioids could do in the UK. 'We already have the highest overdose rate in Europe. Nitazenes could make it way, way worse. 'This is a very serious public health emergency that's not being taken seriously enough.' He added: 'I am scared. There's almost one person dying every day from nitazenes and most people haven't even heard of it. 'If it was anything else, there would be national panic. The government hasn't grasped the urgency of this.' Rolles is starting to see heroin mixed with nitazenes on the streets of Britain. He said: 'It does seem it's getting more [prevalent] as the heroin supply dries up.'


Reuters
3 minutes ago
- Reuters
Bayer adds cancer drug candidate to portfolio with $1.3-billion Kumquat deal
BERLIN, Aug 12 (Reuters) - German pharmaceutical group Bayer ( opens new tab announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug. Under the agreement, Kumquat will be responsible for initiating and completing a phase-Ia study into the drug, a KRAS G12D inhibitor, while Bayer will complete development and commercial activities. Bayer said the deal complements its precision oncology development portfolio in the areas of pancreatic, colorectal and lung cancer. KRAS mutations occur in nearly 25% of human cancers, with the variant targeted by Kumquat's experimental drug still lacking effective treatment options, according to a company statement. Bayer said it has agreed to pay Kumquat up to $1.3 billion, including upfront, clinical and commercial milestones, and additional tiered royalties on net sales. Kumquat, which since its launch in 2019 has also signed agreements with Eli Lilly (LLY.N), opens new tab and Takeda (4502.T), opens new tab, retains an exclusive option to negotiate for participating in profit-loss sharing in the United States under the deal with Bayer. "This collaboration provides Kumquat the financial resources to accelerate its broader clinical pipeline for long-term value," Kumquat CEO Yi Liu said in a statement shared by Bayer.